EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim By Ogkologos - September 18, 2025 412 0 Facebook Twitter Google+ Pinterest WhatsApp Vivlipeg is highly similar to the reference product Neulasta, which was authorised in the EU in 2002 Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR FDA Approves Belzutifan for Cancers Associated with Von Hippel-Lindau Disease August 17, 2021 TRACERx: Using blood tests to track lung cancer May 1, 2023 Opinion: ‘We’re making headway, but we can’t be complacent’ February 11, 2021 Spending Review 2021: Promising commitments, but a lot of unanswered questions October 27, 2021 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Fruquintinib Prostate cancer: Lessons Learned from My Breast Cancer “Nothing about us without us”: Why we’re working in partnership with... Coping With Cancer Recurrence: My Perspective As Both a Patient and...
